To the Editor We have read with great interest the article by Hank et al.¹ The authors indicated that neoadjuvant therapy (NAT) could reduce the rate of clinically relevant postoperative pancreatic fistula (CR-POPF). In addition, they demonstrated that CR-POPF is associated with a significant reduction in long-term survival for patients with pancreatic cancer with NAT.

中文翻译：

---

胰腺瘘在新辅助治疗胰腺癌切除患者中的预后价值。

致编辑我们非常感兴趣地阅读了Hank等人的文章。¹作者指出，新辅助疗法（NAT）可以降低临床相关的术后胰瘘（CR-POPF）的发生率。此外，他们证明了CR-POPF与NAT胰腺癌患者的长期生存率显着降低有关。